Rapid syndromic molecular testing in pneumonia: The current landscape and future potential

Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Poole, Stephen, Clark, Tristan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of The British Infection Association. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132381/
https://www.ncbi.nlm.nih.gov/pubmed/31809764
http://dx.doi.org/10.1016/j.jinf.2019.11.021
_version_ 1783517424656580608
author Poole, Stephen
Clark, Tristan W.
author_facet Poole, Stephen
Clark, Tristan W.
author_sort Poole, Stephen
collection PubMed
description Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia.
format Online
Article
Text
id pubmed-7132381
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Ltd on behalf of The British Infection Association.
record_format MEDLINE/PubMed
spelling pubmed-71323812020-04-08 Rapid syndromic molecular testing in pneumonia: The current landscape and future potential Poole, Stephen Clark, Tristan W. J Infect Article Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia. Published by Elsevier Ltd on behalf of The British Infection Association. 2020-01 2019-12-03 /pmc/articles/PMC7132381/ /pubmed/31809764 http://dx.doi.org/10.1016/j.jinf.2019.11.021 Text en Crown Copyright © 2019 Published by Elsevier Ltd on behalf of The British Infection Association. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Poole, Stephen
Clark, Tristan W.
Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title_full Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title_fullStr Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title_full_unstemmed Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title_short Rapid syndromic molecular testing in pneumonia: The current landscape and future potential
title_sort rapid syndromic molecular testing in pneumonia: the current landscape and future potential
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132381/
https://www.ncbi.nlm.nih.gov/pubmed/31809764
http://dx.doi.org/10.1016/j.jinf.2019.11.021
work_keys_str_mv AT poolestephen rapidsyndromicmoleculartestinginpneumoniathecurrentlandscapeandfuturepotential
AT clarktristanw rapidsyndromicmoleculartestinginpneumoniathecurrentlandscapeandfuturepotential

Ejemplares similares